A phase I/II study of flavopiridol [alvocidib] in relapsed or refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).
Phase of Trial: Phase I/II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Alvocidib (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 May 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
- 17 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Mar 2012 Planned end date changed from 1 Nov 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.